- Home
- LPCN vs ALLR Comparison
LPCN vs ALLR Comparison
Compare LPCN & ALLR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LPCN
- ALLR
- Stock Information
- Founded
- LPCN 1997
- ALLR 2004
- Country
- LPCN United States
- ALLR United States
- Employees
- LPCN N/A
- ALLR N/A
- Industry
- LPCN Biotechnology: Pharmaceutical Preparations
- ALLR Biotechnology: Pharmaceutical Preparations
- Sector
- LPCN Health Care
- ALLR Health Care
- Exchange
- LPCN Nasdaq
- ALLR Nasdaq
- Market Cap
- LPCN 16.1M
- ALLR 15.8M
- IPO Year
- LPCN N/A
- ALLR N/A
- Fundamental
- Price
- LPCN $3.00
- ALLR $1.01
- Analyst Decision
- LPCN Strong Buy
- ALLR
- Analyst Count
- LPCN 2
- ALLR 0
- Target Price
- LPCN $9.00
- ALLR N/A
- AVG Volume (30 Days)
- LPCN 29.3K
- ALLR 406.8K
- Earning Date
- LPCN 08-07-2025
- ALLR 08-04-2025
- Dividend Yield
- LPCN N/A
- ALLR N/A
- EPS Growth
- LPCN N/A
- ALLR N/A
- EPS
- LPCN N/A
- ALLR N/A
- Revenue
- LPCN $3,674,834.00
- ALLR N/A
- Revenue This Year
- LPCN N/A
- ALLR N/A
- Revenue Next Year
- LPCN N/A
- ALLR N/A
- P/E Ratio
- LPCN N/A
- ALLR N/A
- Revenue Growth
- LPCN N/A
- ALLR N/A
- 52 Week Low
- LPCN $2.68
- ALLR $0.61
- 52 Week High
- LPCN $7.61
- ALLR $7.45
- Technical
- Relative Strength Index (RSI)
- LPCN 40.07
- ALLR 55.55
- Support Level
- LPCN $3.10
- ALLR $0.98
- Resistance Level
- LPCN $3.39
- ALLR $1.10
- Average True Range (ATR)
- LPCN 0.18
- ALLR 0.06
- MACD
- LPCN -0.00
- ALLR 0.01
- Stochastic Oscillator
- LPCN 0.00
- ALLR 65.11
About LPCN Lipocine Inc.
Lipocine Inc is a clinical-stage biopharmaceutical company, that is engaged in research and development for the delivery of drugs using its proprietary delivery technology. Its principal operation is to provide oral delivery solutions for existing drugs. Lipocine develops its drug candidates or it develops drug candidates on behalf of or in collaboration with corporate partners. The company's product TLANDO is an oral testosterone replacement therapy ("TRT"). It also has other products in the pipeline such as LPCN 1144, TLANDO, TLANDO XR, LPCN 1148, LPCN 1107, LPCN 1154, and LIP'RAL7 Technology. The Company has a single reportable segment, research, and development for the delivery of drugs using its proprietary delivery technology.
About ALLR Allarity Therapeutics Inc.
Allarity Therapeutics Inc is a clinical-stage, precision medicine pharmaceutical company focused on developing novel anti-cancer therapeutics for patients with high unmet medical needs. The company is actively advancing the development of stenoparib, an orally available, small-molecule inhibitor for patients with advanced recurrent ovarian cancer. It is leveraging its proprietary Drug Response Predictor (DRP) technology to refine patient selection and improve clinical outcomes. The company operates as a single operating and reporting segment (developing a treatment for ovarian cancer) in two geographic areas: Denmark and the United States.